Australian company pioneering Cavadextrin for regression of atherosclerosis
Newsmaker, the Australian Press Release Distribution Service has published the news on “An Australian pioneering a medical breakthrough treatment that
A forum for researchers, students and applicants in the field of cyclodextrin technology
Newsmaker, the Australian Press Release Distribution Service has published the news on “An Australian pioneering a medical breakthrough treatment that
Cloudbreak Therapeutics, LLC has sponsored a multicenter, randomized, double-masked, vehicle-controlled, parallel group study using CBT-008 (buffered solution of methyl BCD)
Cyclodextrins (CDs) are used not only as pharmaceutical excipients but also as active pharmaceutical ingredients. CDs can act as artificial
A promising therapy for atherosclerosis treatment was designed by targeting LXR receptor (LXR) on atherosclerotic macrophage, where LXR activation could
Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it
Li-Huei Tsai, director of Picower Institute for Learning and Memory (Massachusetts Institute of Technology) and her coworkers recently filed a patent
Microencapsulation of drugs with cyclodextrins (CDs) is a commonly applied strategy to solubilize lipophilic drugs in aqueous environment and/or to
Ozonized (2-Hydroxypropyl)-β-cyclodextrins (Oz-HPbCDs) were produced by direct gas/solid reaction between gaseous ozone (O3) and solid HPbCD. The solid materials obtained
A meta-analysis has been recently published about the dosing of sugammadex (SGM) for neuromuscular blockade (NMB) induced muscle relaxation in
COVID-19 is marked by extensive damage to the respiratory system, often accompanied by systemic manifestations, due to both viral cytopathic